You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
哈藥股份(600664.SH):哈藥總廠頭孢氨苄膠囊通過仿製藥一致性評價
格隆匯 12-29 17:41

格隆匯12月29日丨哈藥股份(600664.SH)公佈,近日,公司分公司哈藥集團製藥總廠(以下簡稱“哈藥總廠”)收到國家藥品監督管理局頒發的關於頭孢氨苄膠囊的《藥品補充申請批件通知書》,該藥品通過仿製藥質量和療效一致性評價。

頭孢氨苄膠囊是常用的口服β-內酰胺類抗感染藥物,適用於敏感菌所致的急性扁桃體炎、咽峽炎、鼻竇炎、支氣管炎、肺炎等呼吸道感染、中耳炎、尿路感染及皮膚軟組織感染等。頭孢氨苄於1967年被發現,此後由葛蘭素史克和禮來等多個公司聯合推向市場。截至本公吿日,哈藥總廠針對該藥品仿製藥質量和療效一致性評價已投入研發費用約750萬元人民幣(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account